JP2013538214A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013538214A5 JP2013538214A5 JP2013526335A JP2013526335A JP2013538214A5 JP 2013538214 A5 JP2013538214 A5 JP 2013538214A5 JP 2013526335 A JP2013526335 A JP 2013526335A JP 2013526335 A JP2013526335 A JP 2013526335A JP 2013538214 A5 JP2013538214 A5 JP 2013538214A5
- Authority
- JP
- Japan
- Prior art keywords
- syk
- pharmaceutically acceptable
- osteoclasts
- optionally
- nasal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000012453 solvate Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 101000996834 Homo sapiens Linker for activation of T-cells family member 2 Proteins 0.000 description 1
- 102100034238 Linker for activation of T-cells family member 2 Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000001332 SRC Human genes 0.000 description 1
- 108060006706 SRC Proteins 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10008927.5 | 2010-08-27 | ||
| EP10008927 | 2010-08-27 | ||
| PCT/EP2011/003830 WO2012025186A1 (en) | 2010-08-27 | 2011-07-29 | Triazolopyrazine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013538214A JP2013538214A (ja) | 2013-10-10 |
| JP2013538214A5 true JP2013538214A5 (enExample) | 2015-07-16 |
| JP5951610B2 JP5951610B2 (ja) | 2016-07-13 |
Family
ID=44629489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526335A Expired - Fee Related JP5951610B2 (ja) | 2010-08-27 | 2011-07-29 | トリアゾロピラジン誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9023851B2 (enExample) |
| EP (1) | EP2609098B1 (enExample) |
| JP (1) | JP5951610B2 (enExample) |
| KR (1) | KR20130110163A (enExample) |
| CN (1) | CN103068828B (enExample) |
| AR (1) | AR082726A1 (enExample) |
| AU (1) | AU2011295440B2 (enExample) |
| BR (1) | BR112013004517A2 (enExample) |
| CA (1) | CA2809331C (enExample) |
| EA (1) | EA201300282A1 (enExample) |
| ES (1) | ES2614128T3 (enExample) |
| IL (1) | IL224869A (enExample) |
| MX (1) | MX2013002198A (enExample) |
| SG (1) | SG188296A1 (enExample) |
| WO (1) | WO2012025186A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9120804B2 (en) | 2012-02-21 | 2015-09-01 | Merck Patent Gmbh | 8-substituted 2-amino-[1,2,4] triazolo [1, 5-A] pyrazines as Syk tryrosine kinase inhibitors and GCN2 serin kinase inhibitors |
| JP6049768B2 (ja) * | 2012-03-07 | 2016-12-21 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | トリアゾロピラジン誘導体 |
| EP3550031A1 (en) | 2012-07-24 | 2019-10-09 | Pharmacyclics, LLC | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| BR112015004427A2 (pt) | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | compostos , métodos para o tratamento de um estado inflamatório , da artrite reumatóide , da asma , de um distúrbio imunológico e de um distúrbio imune e composição farmacêutica |
| CA2903901A1 (en) * | 2013-03-05 | 2014-09-12 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| CN105026398B (zh) * | 2013-03-05 | 2018-05-18 | 默克专利股份公司 | 用于治疗疾病诸如癌症的三唑并[4,5-d]嘧啶衍生物 |
| EP2994471B1 (en) * | 2013-05-06 | 2017-05-17 | Merck Patent GmbH | Macrocycles as kinase inhibitors |
| WO2015017402A1 (en) * | 2013-07-29 | 2015-02-05 | Board Of Regents Of The University Of Nebraska | Compositions and methods for the treatment of biofilm infections |
| EP3137454A1 (en) | 2014-04-28 | 2017-03-08 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| KR101756934B1 (ko) | 2014-07-08 | 2017-07-12 | 연세대학교 산학협력단 | 피롤로[1,2-a]피라진 유도체, 이의 약학적으로 허용가능한 염, 이들 화합물의 제조방법 및 이를 유효성분으로 함유하는 골다공증 치료 또는 예방용 약학조성물 |
| ES2970715T3 (es) | 2016-12-22 | 2024-05-30 | Prec Pharmaceuticals Inc | Composiciones y métodos para inhibir la actividad de la arginasa |
| CR20230030A (es) | 2018-02-27 | 2023-03-10 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441) |
| MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
| MX2021000116A (es) | 2018-07-05 | 2021-03-29 | Incyte Corp | Derivados de pirazina fusionados como inhibidores de a2a/a2b. |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5227032B2 (ja) * | 2005-02-03 | 2013-07-03 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼの阻害剤として有用なピロロピリミジン |
| JP4652906B2 (ja) * | 2005-06-30 | 2011-03-16 | 富士夫 宮脇 | 振動型マイクロインジェクション装置 |
| CA2636701C (en) * | 2006-01-27 | 2014-08-05 | Shanghai Hengrui Pharmaceutical Co. Ltd. | Pyrrolo [3,2-c] pyridine-4-one 2-indolinone protein kinase inhibitors |
| WO2008057994A2 (en) * | 2006-11-03 | 2008-05-15 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| WO2008118823A2 (en) | 2007-03-26 | 2008-10-02 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| KR20100132550A (ko) | 2008-04-16 | 2010-12-17 | 포톨라 파마슈티컬스, 인코포레이티드 | ｓｙｋ 또는 ＪＡＫ 키나제 억제제로서의 ２,６－디아미노-피리미딘－５－일－카르복스아미드 |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| KR20110033223A (ko) | 2008-06-20 | 2011-03-30 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| TWI453207B (zh) | 2008-09-08 | 2014-09-21 | Signal Pharm Llc | 胺基三唑并吡啶，其組合物及使用其之治療方法 |
| CN102459258B (zh) * | 2009-06-05 | 2015-11-25 | 赛福伦公司 | 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途 |
| WO2011086098A1 (en) * | 2010-01-15 | 2011-07-21 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Novel substituted bicyclic triazole derivatives as gamma secretase modulators |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
-
2011
- 2011-07-29 BR BR112013004517A patent/BR112013004517A2/pt not_active Application Discontinuation
- 2011-07-29 EP EP11738630.0A patent/EP2609098B1/en not_active Not-in-force
- 2011-07-29 CN CN201180041643.5A patent/CN103068828B/zh not_active Expired - Fee Related
- 2011-07-29 EA EA201300282A patent/EA201300282A1/ru unknown
- 2011-07-29 CA CA2809331A patent/CA2809331C/en not_active Expired - Fee Related
- 2011-07-29 US US13/819,120 patent/US9023851B2/en active Active
- 2011-07-29 KR KR20137007843A patent/KR20130110163A/ko not_active Withdrawn
- 2011-07-29 MX MX2013002198A patent/MX2013002198A/es not_active Application Discontinuation
- 2011-07-29 WO PCT/EP2011/003830 patent/WO2012025186A1/en not_active Ceased
- 2011-07-29 JP JP2013526335A patent/JP5951610B2/ja not_active Expired - Fee Related
- 2011-07-29 SG SG2013014006A patent/SG188296A1/en unknown
- 2011-07-29 ES ES11738630.0T patent/ES2614128T3/es active Active
- 2011-07-29 AU AU2011295440A patent/AU2011295440B2/en not_active Ceased
- 2011-08-26 AR ARP110103111 patent/AR082726A1/es unknown
-
2013
- 2013-02-21 IL IL224869A patent/IL224869A/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013538214A5 (enExample) | ||
| US10568868B2 (en) | Methods and compositions for treating metabolic reprogramming disorders | |
| JP2013536208A5 (enExample) | ||
| ES2558477T3 (es) | Triazoles sustituidos útiles como inhibidores de AXL | |
| ES2761406T3 (es) | Protección transitoria de células normales durante una quimioterapia | |
| ES2622138T3 (es) | Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa | |
| ES2563979T3 (es) | Método para producción de partículas de compuesto orgánico pulverizadas | |
| JP2014526447A5 (enExample) | ||
| JP2014509313A5 (enExample) | ||
| JP2013534227A5 (enExample) | ||
| ES2875584T3 (es) | Formulación para inhalación líquida que comprende RPL554 | |
| US20180303838A1 (en) | Transient protection of hematopoietic stem and progenitor cells against ionizing radiation | |
| AU2024219564A1 (en) | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs | |
| JP2013544781A5 (enExample) | ||
| BR112012030010A2 (pt) | 5-flúor-1h-pirazolopiridinas substituídas e seu uso | |
| ES2795879T3 (es) | Aplicaciones terapéuticas de ectoína | |
| UA121104C2 (uk) | Гетероциклічні сполуки і їх застосування | |
| US11980633B2 (en) | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | |
| EA201491674A1 (ru) | Новые фармацевтические композиции | |
| JP2015505541A5 (enExample) | ||
| CN105939717A (zh) | 治疗和预防同种抗体驱动的慢性移植物抗宿主病的方法 | |
| AR039317A1 (es) | Proceso para la preparacion de una suspension esteril de particulas de dipropionato de beclometasona para administracion por inhalacion | |
| US11844779B2 (en) | PKC-Delta-I inhibitor formulations and uses thereof | |
| KR101838764B1 (ko) | (ｅ)-4-카복시스티릴-4-클로로벤질설폰의 개선된 안정한 수성 제형 | |
| ES2530223T3 (es) | Combinación de insulina con derivados de triazina y su uso para tratar la diabetes |